New blood test may predict immunotherapy success in cancer patients
NCT ID NCT02840058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether measuring specific immune responses (anti-telomerase T cells) in the blood can help predict how well cancer patients will respond to immunotherapy drugs like anti-PD1/PDL1. Researchers enrolled 295 adults with advanced or metastatic cancer who were about to start such treatment. The goal was to see if these immune markers could serve as a tool to forecast treatment effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Nord Franche-Comté
Montbéliard, 25200, France
-
Hôpital Saint-Louis - APHP
Paris, France
-
Institut Paoli Calmette
Marseille, France
-
University Hospital of Besançon
Besançon, 25000, France